{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:48:52Z","timestamp":1788482932303,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Complementary Therapies in Clinical Practice"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ctcp.2020.101281","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T19:39:59Z","timestamp":1607024399000},"page":"101281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-0633","authenticated-orcid":false,"given":"Sahar","family":"Rafiee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"Ghavami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-8006","authenticated-orcid":false,"given":"Erfan","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Safari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1194-9687","authenticated-orcid":false,"given":"Gholamreza","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctcp.2020.101281_bib1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2147\/CLEP.S144368","article-title":"Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes","volume":"9","author":"Simeone","year":"2017","journal-title":"Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.ctcp.2020.101281_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/nu11040872","article-title":"Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation","volume":"11","author":"Yang","year":"2019","journal-title":"Nutrients"},{"issue":"43","key":"10.1016\/j.ctcp.2020.101281_bib3","doi-asserted-by":"crossref","first-page":"9488","DOI":"10.3748\/wjg.v22.i43.9488","article-title":"Nonalcoholic fatty liver disease - a multisystem disease?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ctcp.2020.101281_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology (Baltimore, Md"},{"issue":"4","key":"10.1016\/j.ctcp.2020.101281_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.ctcp.2020.101281_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3904\/kjim.2017.343","article-title":"Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity","volume":"33","author":"Kwak","year":"2018","journal-title":"Korean J. Intern. Med. (Korean Ed.)"},{"issue":"7117","key":"10.1016\/j.ctcp.2020.101281_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature05354","article-title":"Resveratrol improves health and survival of mice on a high-calorie diet","volume":"444","author":"Baur","year":"2006","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ctcp.2020.101281_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd2060","article-title":"Therapeutic potential of resveratrol: the in vivo evidence","volume":"5","author":"Baur","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.ctcp.2020.101281_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/1940-6207.CAPR-08-0160","article-title":"Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials","volume":"2","author":"Bishayee","year":"2009","journal-title":"Cancer prevention research"},{"issue":"3","key":"10.1016\/j.ctcp.2020.101281_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0008-6363(00)00102-4","article-title":"Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes","volume":"47","author":"Hung","year":"2000","journal-title":"Cardiovasc. Res."},{"issue":"2\u20133","key":"10.1016\/j.ctcp.2020.101281_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12035-010-8111-y","article-title":"Resveratrol as a therapeutic agent for neurodegenerative diseases","volume":"41","author":"Sun","year":"2010","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.ctcp.2020.101281_bib12","first-page":"1269","article-title":"Anti-inflammatory activity of resveratrol prevents inflammation by inhibiting NFkappaB in animal models of acute pharyngitis","volume":"17","author":"Zhou","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1\u20133","key":"10.1016\/j.ctcp.2020.101281_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2010.03.043","article-title":"Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation","volume":"636","author":"Zhang","year":"2010","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.ctcp.2020.101281_bib14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s11274-010-0325-7","article-title":"Antimicrobial activity and effects of resveratrol on human pathogenic bacteria","volume":"26","author":"Paulo","year":"2010","journal-title":"World J. Microbiol. Biotechnol."},{"issue":"3","key":"10.1016\/j.ctcp.2020.101281_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/biomedicines6030091","article-title":"Resveratrol: a double-edged sword in health benefits","volume":"6","author":"Salehi","year":"2018","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.ctcp.2020.101281_bib16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2006.11.013","article-title":"Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha","volume":"127","author":"Lagouge","year":"2006","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctcp.2020.101281_bib17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/db09-0482","article-title":"AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol","volume":"59","author":"Um","year":"2010","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ctcp.2020.101281_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2012.01.032","article-title":"Finding a target for resveratrol","volume":"148","author":"Tennen","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ctcp.2020.101281_bib19","first-page":"226","article-title":"Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial, Digestive and liver disease","volume":"47","author":"Chen","year":"2015","journal-title":"off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"issue":"10","key":"10.1016\/j.ctcp.2020.101281_bib20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","article-title":"Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease","volume":"34","author":"Faghihzadeh","year":"2014","journal-title":"Nutr. Res. (N.Y.)"},{"issue":"4","key":"10.1016\/j.ctcp.2020.101281_bib21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","article-title":"Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease","volume":"51","author":"Heeboll","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ctcp.2020.101281_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/07315724.2017.1392264","article-title":"Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial","volume":"37","author":"Asghari","year":"2018","journal-title":"J. Am. Coll. Nutr."},{"issue":"2","key":"10.1016\/j.ctcp.2020.101281_bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.15171\/apb.2018.036","article-title":"Effects of pharmacologic dose of resveratrol supplementation on oxidative\/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial","volume":"8","author":"Asghari","year":"2018","journal-title":"Adv. Pharmaceut. Bull."},{"issue":"12","key":"10.1016\/j.ctcp.2020.101281_bib24","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"8","key":"10.1016\/j.ctcp.2020.101281_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161792","article-title":"Efficacy of resveratrol supplementation against non-alcoholic fatty liver disease: a meta-analysis of placebo-controlled clinical trials","volume":"11","author":"Zhang","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.ctcp.2020.101281_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.15403\/jgld.2014.1121.261.ely","article-title":"Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis","volume":"26","author":"Elgebaly","year":"2017","journal-title":"J. Gastrointest. Liver Dis. : JGLD"},{"key":"10.1016\/j.ctcp.2020.101281_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ctcp.2020.101281_bib28","first-page":"1","article-title":"No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease, International journal for vitamin and nutrition research. Internationale Zeitschrift Fur Vitamin- und Ernahrungsforschung","author":"Farzin","year":"2019","journal-title":"J. Int. Vitaminol. Nutr."},{"issue":"3","key":"10.1016\/j.ctcp.2020.101281_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/diseases6030080","article-title":"Potential therapeutic benefits of herbs and supplements in patients with NAFLD","volume":"6","author":"Perumpail","year":"2018","journal-title":"Diseases"},{"issue":"7","key":"10.1016\/j.ctcp.2020.101281_bib30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.nut.2013.11.016","article-title":"Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation","volume":"30","author":"Andrade","year":"2014","journal-title":"Nutrition"},{"issue":"25","key":"10.1016\/j.ctcp.2020.101281_bib31","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4254\/wjh.v7.i25.2597","article-title":"Dietary supplements and pediatric non-alcoholic fatty liver disease: present and the future","volume":"7","author":"Rahimlou","year":"2015","journal-title":"World J. Hepatol."},{"issue":"5","key":"10.1016\/j.ctcp.2020.101281_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-277X.2005.00634.x","article-title":"Body mass index and waist circumference in non\u2010alcoholic fatty liver disease","volume":"18","author":"Rocha","year":"2005","journal-title":"J. Hum. Nutr. Diet."},{"key":"10.1016\/j.ctcp.2020.101281_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/362147","article-title":"Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalcoholic fatty liver disease","author":"Zheng","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"issue":"1","key":"10.1016\/j.ctcp.2020.101281_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clnu.2014.03.009","article-title":"Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials","volume":"34","author":"Liu","year":"2015","journal-title":"Clin. Nutr."},{"issue":"6","key":"10.1016\/j.ctcp.2020.101281_bib35","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3945\/ajcn.113.082024","article-title":"Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials","volume":"99","author":"Liu","year":"2014","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.ctcp.2020.101281_bib36","first-page":"30","article-title":"What is the real function of the liver 'function' tests?","volume":"81","author":"Hall","year":"2012","journal-title":"Ulster Med. J."},{"issue":"2","key":"10.1016\/j.ctcp.2020.101281_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172666","article-title":"High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men","volume":"12","author":"Lee","year":"2017","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.ctcp.2020.101281_bib38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ihj.2014.08.006","article-title":"Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-\u03b1","volume":"66","author":"Ajmal","year":"2014","journal-title":"Indian Heart J."},{"issue":"1","key":"10.1016\/j.ctcp.2020.101281_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3803\/EnM.2013.28.1.41","article-title":"Tumor necrosis factor-\u03b1 as a predictor for the development of nonalcoholic fatty liver disease: a 4-year follow-up study","volume":"28","author":"Seo","year":"2013","journal-title":"Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.ctcp.2020.101281_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027081","article-title":"Activation of Sirt1 by resveratrol inhibits TNF-\u03b1 induced inflammation in fibroblasts","volume":"6","author":"Zhu","year":"2011","journal-title":"PloS One"}],"container-title":["Complementary Therapies in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1744388120311567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1744388120311567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:51:36Z","timestamp":1761677496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1744388120311567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":40,"alternative-id":["S1744388120311567"],"URL":"https:\/\/doi.org\/10.1016\/j.ctcp.2020.101281","relation":{},"ISSN":["1744-3881"],"issn-type":[{"value":"1744-3881","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Complementary Therapies in Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctcp.2020.101281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101281"}}